A prosztatarák molekuláris altípusai és célzott terápiás kilátásai

Translated title of the contribution: Molecular subtypes and perspectives of targeted therapies in prostate cancer

Szarvas Tibor, Csizmarik Anita, Szűcs Miklós, P. Nyírády

Research output: Contribution to journalReview article

Abstract

In the last few years, the emergence of new high throughput molecular technologies allowed a never-before-seen insight into the genetic, epigenetic, transcriptomic and proteomic background of cancers. These studies have been performed in a large number of patients’ samples and provided a great amount of data. Current efforts to translate these new findings into therapeutic strategies are ongoing, but already provided significant information which may change clinical practice in the near future. As a result of this development, the most frequent molecular alterations and affected pathways responsible for the formation and progression of prostate cancer have been identified. In this review, we provide an overview on the current progress in primary and metastatic prostate cancer research focusing on the molecular subtype classification and the most frequently dysregulated pathways, such as androgen signaling, PI3K pathway, cell cycle and DNA repair regulation. In this context, we highlight therapies already approved or are currently under clinical investigation for prostate cancer.

Original languageHungarian
Pages (from-to)252-263
Number of pages12
JournalOrvosi hetilap
Volume160
Issue number7
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Prostatic Neoplasms
Phosphatidylinositol 3-Kinases
Epigenomics
DNA Repair
Proteomics
Androgens
Cell Cycle
Therapeutics
Technology
Research
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A prosztatarák molekuláris altípusai és célzott terápiás kilátásai. / Tibor, Szarvas; Anita, Csizmarik; Miklós, Szűcs; Nyírády, P.

In: Orvosi hetilap, Vol. 160, No. 7, 01.02.2019, p. 252-263.

Research output: Contribution to journalReview article

Tibor, Szarvas ; Anita, Csizmarik ; Miklós, Szűcs ; Nyírády, P. / A prosztatarák molekuláris altípusai és célzott terápiás kilátásai. In: Orvosi hetilap. 2019 ; Vol. 160, No. 7. pp. 252-263.
@article{0bc1d028f8a94b198ea8dcd7f6effcc8,
title = "A prosztatar{\'a}k molekul{\'a}ris alt{\'i}pusai {\'e}s c{\'e}lzott ter{\'a}pi{\'a}s kil{\'a}t{\'a}sai",
abstract = "In the last few years, the emergence of new high throughput molecular technologies allowed a never-before-seen insight into the genetic, epigenetic, transcriptomic and proteomic background of cancers. These studies have been performed in a large number of patients’ samples and provided a great amount of data. Current efforts to translate these new findings into therapeutic strategies are ongoing, but already provided significant information which may change clinical practice in the near future. As a result of this development, the most frequent molecular alterations and affected pathways responsible for the formation and progression of prostate cancer have been identified. In this review, we provide an overview on the current progress in primary and metastatic prostate cancer research focusing on the molecular subtype classification and the most frequently dysregulated pathways, such as androgen signaling, PI3K pathway, cell cycle and DNA repair regulation. In this context, we highlight therapies already approved or are currently under clinical investigation for prostate cancer.",
keywords = "Genetic aberration, Molecular subtype, Mutation, Prostate cancer, Targeted therapy",
author = "Szarvas Tibor and Csizmarik Anita and Szűcs Mikl{\'o}s and P. Ny{\'i}r{\'a}dy",
year = "2019",
month = "2",
day = "1",
doi = "10.1556/650.2019.31315",
language = "Hungarian",
volume = "160",
pages = "252--263",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "7",

}

TY - JOUR

T1 - A prosztatarák molekuláris altípusai és célzott terápiás kilátásai

AU - Tibor, Szarvas

AU - Anita, Csizmarik

AU - Miklós, Szűcs

AU - Nyírády, P.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - In the last few years, the emergence of new high throughput molecular technologies allowed a never-before-seen insight into the genetic, epigenetic, transcriptomic and proteomic background of cancers. These studies have been performed in a large number of patients’ samples and provided a great amount of data. Current efforts to translate these new findings into therapeutic strategies are ongoing, but already provided significant information which may change clinical practice in the near future. As a result of this development, the most frequent molecular alterations and affected pathways responsible for the formation and progression of prostate cancer have been identified. In this review, we provide an overview on the current progress in primary and metastatic prostate cancer research focusing on the molecular subtype classification and the most frequently dysregulated pathways, such as androgen signaling, PI3K pathway, cell cycle and DNA repair regulation. In this context, we highlight therapies already approved or are currently under clinical investigation for prostate cancer.

AB - In the last few years, the emergence of new high throughput molecular technologies allowed a never-before-seen insight into the genetic, epigenetic, transcriptomic and proteomic background of cancers. These studies have been performed in a large number of patients’ samples and provided a great amount of data. Current efforts to translate these new findings into therapeutic strategies are ongoing, but already provided significant information which may change clinical practice in the near future. As a result of this development, the most frequent molecular alterations and affected pathways responsible for the formation and progression of prostate cancer have been identified. In this review, we provide an overview on the current progress in primary and metastatic prostate cancer research focusing on the molecular subtype classification and the most frequently dysregulated pathways, such as androgen signaling, PI3K pathway, cell cycle and DNA repair regulation. In this context, we highlight therapies already approved or are currently under clinical investigation for prostate cancer.

KW - Genetic aberration

KW - Molecular subtype

KW - Mutation

KW - Prostate cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85061237129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061237129&partnerID=8YFLogxK

U2 - 10.1556/650.2019.31315

DO - 10.1556/650.2019.31315

M3 - Review article

C2 - 30741006

AN - SCOPUS:85061237129

VL - 160

SP - 252

EP - 263

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 7

ER -